Breaking News

Innovent Biologics, Bolt Biotherapeutics Enter Immuno-oncology Alliance

Will leverage Innovent's therapeutic antibody portfolio and discovery capability against undisclosed oncology targets in combination with Bolt's ISAC technology

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Innovent Biologics, Inc., a biopharmaceutical company that develops, manufactures and commercializes medicines for cancer, metabolic, autoimmune and other diseases, and Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents, entered a collaboration to research and develop three new anti-cancer therapeutic immune-stimulating antibody conjugate (ISAC) candidates.   The companies will leverage Innovent’s therapeutic antibody portf...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters